Endothelial Cell News 4.01 January 14, 2019 | |
| |
TOP STORYMOV10 binding circ-DICER1 regulated the cell viability, migration, and tube formation of glioma-exposed endothelial cells (GECs). In addition, circ-DICER1 acted as a molecular sponge to adsorb miR-103a-3p /miR-382-5p and impaired the negative regulation of miR-103a-3p /miR-382-5p on ZIC4 in GECs. [J Exp Clin Cancer Res] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Resistin treatment activated the phosphatidylinositol-3-kinase (PI3K) and Akt signaling pathways, while PI3K and Akt inhibitors or siRNA diminished resistin-induced VEGF-A expression. In vitro and in vivo studies revealed the downregulation of miR-16-5p in resistin-induced VEGF-A expression and endothelial progenitor cell angiogenesis. [Cell Death Dis] Full Article 53BP1 Deficiency Promotes Pathological Neovascularization in Proliferative Retinopathy Knockdown of 53BP1 in endothelial cells (ECs) in vitro resulted in enhanced proliferation and reduced apoptosis of the cells under hypoxic conditions. Upon 53BP1 knockdown, ECs displayed increased homologous recombination (HR) rate in hypoxia. Treatment with an HR inhibitor reversed the hyper-proliferative angiogenic phenotype associated with 53BP1 deficiency in retinopathy of prematurity. [Thromb Haemost] Abstract Researchers showed that recombinant galectin-8 activated endothelial nitric oxide synthase (eNOS), induced S-nitrosylation of p120-catenin and dissociation of adherens junction, leading to hyperpermeability of the human endothelial cell line EAhy926. [Carcinogenesis] Abstract In vitro analyses revealed that exosomes secreted by endothelial progenitor cells (EPC-Exos) enhanced the proliferation, migration, and angiogenic capacity of endothelial cells in an miR-126-dependent manner. Further, EPC-Exos downregulated SPRED1 and activated Raf/ERK signaling. [Stem Cell Res Ther] Full Article Using a customized monolayer permeability assay in human pulmonary endothelial cells and microtubule (MT) fractionation, the authors observed that heat-killed S. aureus-induced barrier disruption was accompanied by MT destabilization and increased histone deacetylase-6 activity resulting from elevated reactive oxygen species production. [J Biol Chem] Abstract | Full Article Scientists observed that fibrinopeptide A (FPA) stimulated the generation of C-reactive protein (CRP), IL-1β, and IL-6 in HUVECS; and anti-IL-1β and anti-IL-6 neutralizing antibodies did not alter FPA-induced CRP expression in HUVECs. The subchronic administration of FPA into rats increased plasma FPA and CRP levels. [J Cell Physiol] Abstract Didymin by Suppressing NF-κB Activation Prevents VEGF-Induced Angiogenesis In Vitro and In Vivo Didymin significantly prevented the VEGF-induced endothelial tube formation in culture. Didymin also attenuated the VEGF-induced generation of reactive oxygen species, activation of NF-κB and the expression of adhesion molecules such as vascular cell adhesion molecule-1, intercellular adhesion molecule-1, and E-selectin in HUVECs. Further, didymin also prevented VEGF-induced microvessel sprouting in ex vivo mouse aortic rings. [Vascul Pharmacol] Abstract | Graphical Abstract To examine the role of A disintegrin and metalloprotease 15 (ADAM15) in angiogenesis, researchers performed in vitro Matrigel assays and monocyte adhesion assays using HUVECs transfected with ADAM15 siRNA. Finally, to investigate whether angiogenic mediators were affected by ADAM15, cytokines in ADAM15 siRNA-transfected HUVEC-conditioned medium were measured. [Cells] Full Article Investigators examined whether bioengineered exosomes derived from cardiac progenitor cells (CPCexo) transfected with a pro-angiogenic miR-322 (CPCexo-322) could improve therapeutic efficacy in a mouse model of myocardial infarction as compared to CPCexo. The treatment of cultured human endothelial cells (ECs) with CPCexo-322 resulted in a greater angiogenic response, as determined by increased EC migration and capillary tube formation via increased Nox2-derived reactive oxygen species. [Antioxidants] Full Article Subscribe to one of our other 19 science newsletters such as Extracellular Matrix News & Cell Therapy News. | |
| |
REVIEWSThe authors discuss the role of EPCR and PAR-1 reciprocal interactions in cancer progression as well as potential therapeutic options targeted specifically to interact with EPCR/PAR-1-induced signaling in cancer patients. [Cancers] Full Article Visit our reviews page to see a complete list of reviews in the endothelial cell research field. | |
| |
INDUSTRY NEWSSamsung Bioepis Partners with 3SBio to Expand Biosimilar Business into China Samsung Bioepis Co., Ltd. announced that its rapidly growing biosimilar business will expand into mainland China through a licensing agreement with 3SBio Inc. The agreement covers multiple biosimilar candidates from Samsung Bioepis, including SB8, a biosimilar candidate referencing AVASTIN®. [Samsung Bioepis Co., Ltd.] Press Release URI Launches Alzheimer’s Drug Trial It’s a first for the University of Rhode Island (URI), and a big one: the first time the university has sponsored a clinical trial of a drug treatment. Expected to begin enrolling in April 2019, The BEACON Study will be the first Alzheimer’s drug trial to explore whether a specific kind of inflammation in the brain’s blood vessels plays a role in the disease. [University of Rhode Island] Press Release LIU’s Dr. Richard Nader Is Awarded Fulbright Scholarship to India Dr. Richard Nader, Chief Research and International Officer at Long Island University (LIU), has been selected for a 2019-2020 Fulbright-Nehru U.S. International Education Administrators award to India. This particular Fulbright program is a specially designed, short-term intensive program to connect U.S. universities to opportunities in India that match the interests and priority areas of LIU. [Long Island University] Press Release | |
| |
POLICY NEWSIf the Shutdown Drags On at FDA, It Will Put Anticipated New Treatments in Jeopardy The government shutdown could soon jeopardize highly anticipated new drugs from Janssen, Sanofi and Novartis for depression, diabetes and multiple sclerosis, as well as a host of other potential new therapies, according to a STAT analysis of upcoming regulatory decision dates. [STAT News] Editorial Open-Access Row Prompts Editorial Board of Elsevier Journal to Resign The editorial board of an influential scientometrics journal — the Journal of Informetrics — has resigned in protest over the open-access policies of its publisher, Elsevier, and launched a competing publication. [Nature News] Editorial Serbia Is Rethinking Science — But the Reforms Could Cost Hundreds of Jobs The government says that it is keen to revitalize and invest more in its cash-starved research system, which has an annual budget of about €100 million (US$115 million) and last put out a grant call nearly a decade ago. But some scientists say that the reforms, although badly needed, will lead to hundreds of university researchers losing their jobs. [Nature News] Editorial
| |
EVENTSNEW Gordon Research Conference: From Molecular & Cellular Insights to Therapeutic Approaches in Atherosclerosis Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellows – Vascular Immunology & Immunotherapy (Uppsala University) Assistant Professor – Sarcoma & Skeletal-Related Malignancies (UC Davis School of Medicine) Assistant Professor Tenure Track – Epithelial Cell Biology (Boston Children’s Hospital) Postdoctoral Fellowship – Vascular & Valvular Biology (Yale University School of Medicine) Postdoctoral Fellowship – Cardiovascular Sciences (Medical College of Wisconsin) Tenure Track Faculty Position – Department of Cancer Biology (KUMC) Postdoctoral Fellow – Zebrafish Vascular Biology (NYU Langone Medical Center) Postdoctoral Position – Molecular Neurobiology (San Raffaele Scientific Institute) Senior Research Assistant – Genitourinary Medical Oncology (MD Anderson Cancer Center) Assistant/Associate Adjunct Professor – Cardiovascular Medicine (UC Davis) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Endothelial Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|